About Professor Pallav Shah

Respiratory Consultant

Lung Health

Sub-specialties: COPD, Emphysema, Asthma, Bronchoscopy, EBUS, Lung Cancer Screening, Respiratory Medicine.

Professor Shah clinical experience and understanding of the impacts of respiratory disease on patients’ everyday lives has led to Professor Shah pioneering novel bronchoscopic treatments and procedures which have considerably advanced the techniques for tissue diagnosis.

Overview

Bookings: bookings.lunghealth@onewelbeck.com

Tel: 020 3653 2006

Professor Shah clinical experience and understanding of the impacts of respiratory disease on patients’ everyday lives has led to Professor Shah pioneering novel bronchoscopic treatments and procedures which have considerably advanced the techniques for tissue diagnosis.

Areas of Expertise

Professor Shah treats various conditions including the following

  • COPD
  • Emphysema
  • Asthma

Some of the treatments and procedures he offers are:

  • Bronchoscopy
  • EBUS
  • Lung cancer screening

About Professor Pallav Shah

Professor Pallav Shah has extensive experience in the diagnosis and treatment of all aspects of respiratory disease.  His clinical experience and understanding of the impacts of respiratory disease on patients’ everyday lives has led to Professor Shah pioneering novel bronchoscopic treatments and procedures which have considerably advanced the techniques for tissue diagnosis in lung cancer and revolutionised therapies for COPD, emphysema and asthma.

Alongside his work at OneWelbeck, Professor Pallav Shah works as a Consultant Physician at Chelsea & Westminster Hospital and Royal Brompton Hospital and is a Professor of Respiratory Medicine at National Heart & Lung Institute, Imperial College, London, UK

Personal Biography

Professor Shah has developed techniques for the diagnosis and staging of lung cancer, such as endobronchial ultrasound (EBUS) and navigational bronchoscopy (SuperDimension).  He is also involved in the development of novel techniques for the ablation of peripheral lung tumours and performs a range of procedures including cryotherapy and the insertion of gold markers to enable treatment with the CyberKnife.

Renowned for pushing the boundaries in interventional bronchoscopy and its application to respiratory medicine, Professor Shah has pioneered bronchoscopic lung volume reduction for emphysema with devices such as the Zephyr endobronchial valves, endobronchial coils, vapor treatment, and intrabronchial valves and has more recently been focused on the treatment of COPD with vapor therapy, targeted nerve ablation and the novel Rejuvenair (cryospray) procedure for chronic bronchitis. He was also involved in the development of bronchial thermoplasty for asthma, thus providing a suite of bronchoscopic interventional procedures for some of the most debilitating respiratory diseases.

Professor Shah also sits on multiple advisory boards:

  • August 2007: Specialist Advisor to the NICE Interventional Procedures Programme
  • October 2011 : Specialist Advisor to The Commission on Human Medicines (Cardiovascular, Diabetes, Renal, Respiratory & Allergy Medicines Expert Advisory Group)
  • Jan 2016 to April 2018: Non-Executive Director for British Lung Foundation
  • April 2019: Specialist Advisor to The Commission on Human Medicines (e-cigarettes Expert Advisory Group)
  • October 2019: NICE Centre for Guidelines Expert Advisory Panel
  • January 2020: ACCEA London North West Sub-Committee
  • Aug 2020 : Specialist Advisor to The Commission on Human Medicines (Covid-19 Vaccine  Expert Advisory Group)

Additional Information

Memberships

  • British Thoracic Society
  • International Association for the Study of Lung Cancer
  • Royal College of Physicians
  • World Association of Bronchology & Bronch-Oesophalagy

Awards

  • May 2003: FRCP (UK)
  • Oct 2019: FERS (Fellow of the European Respiratory Society)
  • August 2013 onwards Associate Editor for “Respiration”
  • March 2018 Royal College of Physicians Edinburgh Gold Medal

Research Highlights

Key Publications

  • Khalil K, Agbontaen K, McNally D, Love A, Mandalia S, Banya W, Starren E, Dhunnookchand R, Farne H, Morton R, Davies G, Orhan O, Lai D, Nelson M, Shah PL, Garner JL. Clinical characteristics and 28-day mortality of medical patients admitted with COVID-19 to a central London teaching hospital. J Infect. 2020 Jun 18:S0163-4453(20)30408-4. doi: 10.1016/j.jinf.2020.06.027.
  • van Geffen WH, Slebos DJ, Herth FJ, Kemp SV, Weder W, Shah PL. Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis. Lancet Respir Med. 2019 Feb 7. pii: S2213-2600(18)30431-4. doi: 10.1016/S2213-2600(18)30431-4. [Epub ahead of print].
  • Slebos DJ, Cicenia J, Sciurba FC, Criner GJ, Hartman JE, Garner J, Deslée G, Delage A, Jantz M, Marquette CH, Strange C, Hatipoglu U, Mehta AC, LaPrad AS, Schmid-Bindert G, Herth FJ, Shah PL. Predictors of Response to Endobronchial Coil Therapy in Patients with Advanced Emphysema. Chest. 2019 Feb 21. pii: S0012-3692(19)30188-6. doi: 10.1016/j.chest.2019.02.012. [Epub ahead of print]
  • Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, Sciurba FC, Shah PL, Wahidi MM, de Oliveira HG, Morrissey B, Cardoso PFG, Hays S, Majid A, Pastis N Jr, Kopas L, Vollenweider M, McFadden PM, Machuzak M, Hsia DW, Sung A, Jarad N, Kornaszewska M, Hazelrigg S, Krishna G, Armstrong B, Shargill NS, Slebos DJ; LIBERATE Study Group. A Multicenter RCT of Zephyr® Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198:1151-1164.
  • Sciurba FC, Criner GJ, Strange C, Shah PL, Michaud G, Connolly TA, Deslée G, Tillis WP, Delage A, Marquette CH, Krishna G, Kalhan R, Ferguson JS, Jantz M, Maldonado F, McKenna R, Majid A, Rai N, Gay S, Dransfield MT, Angel L, Maxfield R, Herth FJ, Wahidi MM, Mehta A, Slebos DJ; RENEW Study Research Group. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA. 2016; 315: 2178-89.
  • Herth FJF, Valipour A, Shah PL, Eberhardt RC, Egan J, Ficker JH, Wagner M, Witt C, Liebers U, Hopkins P, Gesierich W, Phillips M, Stanzel F, McNulty WH, Petermann C, Snell G, Gomplemann D. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. The Lancet Respir Med 2016; 4:185-93.
  • Davey C, Zoumot Z, Jordan S, McNulty WH, Carr DH, Hind MD, Hansell DM, Rubens MB, Banya W, Polkey MI, Shah PL, Hopkinson NS. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet. 2015. 386:1066-1073
  • Herth FJ, Eberhardt R, Sterman D, Silvestri GA, Hoffmann H, Shah PL. Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules. Thorax. 2015;70:326-332.
  • Shah PL, Zoumot Z, Singh S, Bicknell SR, Ross ET, Quirring J, Hopkinson NS, Kemp SV. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir Med 2013;1:233-40.
  • Shah PL, Slebos, DJ. Cardoso PFG, Cetti E, Voelker K, Levine B, Rusell ME, Goldin J, Brown M, Cooper JG, Sybrecht GW, on behalf of the EASE trial study group. Bronchoscopic lung volume reduction with exhale airway stents for emphysema (EASE trial): randomised, sham-controlled multicentre trial. Lancet 2011 Sept;378:997-1005.